Medline is the largest provider of medical-surgical products and supply chain solutions in the US... Show more
Medline, Inc. is one of the world's largest providers of medical-surgical products and supply chain solutions, supplying hospitals, surgery centers, long-term care facilities, clinics, and home health providers. Investors follow MDLN because it occupies a foundational role in the healthcare supply chain, combining in-house manufacturing with large-scale distribution and logistics. The company's scale, recurring customer relationships, and hybrid business model make it a notable name in the healthcare products sector.
Medline traces its roots to 1910, when A.L. Mills started a small apron and surgical gown business in Chicago. The modern company was formally established in 1966 by his grandsons, Jim and Jon Mills, and grew for decades as a family-run enterprise. Headquartered in Northfield, Illinois, Medline employs roughly 45,000 people worldwide and operates across more than 100 countries.
In 2021, the Mills family agreed to sell a majority stake to a consortium of private equity firms — Blackstone (BX), Carlyle (CG), and Hellman & Friedman — in a leveraged buyout valued at approximately $34 billion, one of the largest in history. The company returned to the public market in December 2025, listing on the Nasdaq under the ticker MDLN, while the Mills family remained a significant shareholder.
Medline's business is organized around two complementary segments. The Medline Brand segment encompasses products the company manufactures or private-labels itself, including exam gloves, surgical kits, gowns, drapes, wound care, incontinence and skin care products, diagnostic and laboratory supplies, and select durable medical equipment. The Supply Chain Solutions segment distributes third-party medical supplies and provides logistics and procurement services, positioning Medline as a "prime vendor" for healthcare organizations.
This dual model is a defining feature of the company's financial profile. Medline reports a catalog of roughly 335,000 items and operates manufacturing facilities as well as an extensive distribution network that supports next-day delivery to the large majority of its U.S. customers. In fiscal 2024, Medline reported net sales of approximately $25.5 billion and net income of about $1.2 billion, reflecting both its scale and the margin contribution of its branded products.
Medline attracts attention for several long-term reasons. First, its manufacturing-distribution hybrid gives it a different market position from pure distributors: owning production facilities can support higher gross margins and greater control over product specifications, while its distribution network provides volume and customer reach.
Second, healthcare demand for medical-surgical consumables tends to be relatively stable and recurring, driven by ongoing patient care rather than discretionary spending. Long-term supply agreements and prime-vendor relationships contribute to predictable revenue streams across a broad, diversified customer base.
Third, Medline has a substantial presence across the care continuum, from acute-care hospitals to post-acute and home settings, and continues to expand into adjacent areas such as laboratory supplies and international markets. This diversification, combined with the company's scale, supports its role as a key supplier in a large global healthcare market.
Investors should weigh several factors. Medline operates in a competitive industry alongside large distributors and manufacturers, and pricing pressure from healthcare providers and group purchasing organizations can affect margins. The company is also exposed to supply chain and input-cost dynamics, including tariffs and sourcing concentration, which can influence product costs.
Medline carries meaningful debt following its 2021 leveraged buyout, and its financial profile includes interest expense and leverage considerations that management has sought to reduce with IPO proceeds. As a company with global operations, it also faces regulatory, compliance, and macroeconomic risks across the markets it serves. These factors are balanced against the stability of healthcare demand, but they remain important for understanding the company's overall risk profile.
Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps traders and investors identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. Users can efficiently screen thousands of stocks and ETFs to surface ideas that match their own investment strategies. For investors researching healthcare suppliers like Medline or comparing sector peers, the AI Screener offers a practical starting point for building a watchlist.
Medline stands out as a scaled healthcare supplier that combines manufacturing and distribution under one roof, serving a broad and recurring base of healthcare customers. Its return to public markets marked a significant moment for the healthcare sector, and its size, product breadth, and hybrid model keep it relevant for investors evaluating the medical-surgical supply industry. As with any investment, understanding its competitive, financial, and operational risks is essential before forming a view.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Industry PharmaceuticalsOther